Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PDUFA V 'Program' First-Cycle Approval Rates Significantly Higher For All Applications

Executive Summary

Success of review model for new molecular entities and novel biologics should bolster US FDA and industry's stance that Congress reauthorize the user fee program without tinkering with the negotiated agreement, which retains the 'Program' but builds in more flexibility.


Related Content

Inspection Delays Remain For Novel Approvals By US FDA; Will Quality Office Help?
US Generic Reviews: Would Pre-Submission Meetings Be Better Than Six-Month Priority Review?
Biosimilars Will Get PDUFA-Style Reviews Under New User Fee Plan
Sponsors, FDA Reviewers To Get More Flexibility Under New User Fee Program
PDUFA V Reviews Are ‘Best Ever’ For Some Sponsors, Maybe Not FDA
PDUFA V ‘Program’ Gets Positive Evaluation – Except For Inspections
FDA ‘Expedited Review’ Would Shave Off Additional Month For Some ‘Breakthrough’ Products
FDA Review “Program” Tweaks May Include Smaller Mid-Cycle Meetings
“Breakthrough” Review: FDA And Sponsors Discuss Ways To Improve Efficiency





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts